Cadmium Exposure and Incident Cardiovascular Disease
María Téllez-Plaza(Johns Hopkins University), Ana Navas‐Acién(Johns Hopkins University), Jason G. Umans(MedStar Health), Eliseo Güallar(New York University), Kevin A. Francesconi(University of Graz), Barbara V. Howard(National Institutes of Health), Walter Goessler(Graz University of Technology), Richard B. Devereux(NewYork–Presbyterian Hospital), Ellen K. Silbergeld(Johns Hopkins University)
Cited by 352
Related Papers
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
|The Lancet|2002|5.4k
Social Determinants of Health and Diabetes: A Scientific Review
|Diabetes Care|2020|1.6k
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
|The Lancet|2002|1.6k
Lead Exposure and Cardiovascular Disease—A Systematic Review
|Environmental Health Perspectives|2006|1.1k
Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data
|The Lancet Diabetes & Endocrinology|2015|897